SUMO modification modulates the transrepression activity of PLZF

Biochemical and Biophysical Research Communications

Volumn 358, Issue 2, 2007, Pages 475-482

  Chao, Ting Ting ^a,b   Chang, Che Chang ^b   Shih, Hsiu Ming ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Nuclear body; PLZF; SUMO modification; Transcriptional repression

Indexed keywords

ARGININE; LYSINE; PROMYELOCYTIC LEUKEMIA ZINC RINGER; SUMO PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS INCLUSION BODY; CONTROLLED STUDY; GENE REPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SUMOYLATION; TRANSCRIPTION REGULATION; TRANSIENT TRANSFECTION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MUTAGENESIS, SITE-DIRECTED; MUTATION; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SUMO-1 PROTEIN; TRANS-ACTIVATION (GENETICS);

EID: 34248595692     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.04.157     Document Type: Article

References (33)

1. Hay R.T. SUMO: a history of modification. Mol. Cell 18 (2005) 1-12
2. Kerscher O., Felberbaum R., and Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006) 159-180
3. Johnson E.S. Protein modification by sumo. Annu. Rev. Biochem. 73 (2004) 355-382
4. Rodriguez M.S., Dargemont C., and Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276 (2001) 12654-12659
5. Melchior F., Schergaut M., and Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28 (2003) 612-618
6. Gill G. Something about SUMO inhibits transcription. Curr. Opin. Genet. Dev. 15 (2005) 536-541
7. Seeler J.S., and Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4 (2003) 690-699
8. Chang C.C., Lin D.Y., Fang H.I., Chen R.H., and Shih H.M. Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J. Biol. Chem. 280 (2005) 10164-10173
9. Kuo H.Y., Chang C.C., Jeng J.C., Hu H.M., Lin D.Y., Maul G.G., Kwok R.P., and Shih H.M. SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proc. Natl. Acad. Sci. USA 102 (2005) 16973-16978
10. Lin D.Y., Fang H.I., Ma A.H., Huang Y.S., Pu Y.S., Jenster G., Kung H.J., and Shih H.M. Negative modulation of androgen receptor transcriptional activity by daxx. Mol. Cell Biol. 24 (2004) 10529-10541
11. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C., Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S., Hwang M.J., Chang K.S., Maul G.G., and Shih H.M. Role of SUMO-Interacting Motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24 (2006) 341-354
12. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., and Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 11 (2003) 1043-1054
13. Yang S.H., and Sharrocks A.D. SUMO promotes HDAC-mediated transcriptional repression. Mol. Cell 13 (2004) 611-617
14. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss III J.F., and Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147 (1999) 221-234
15. Lallemand-Breitenbach V., Zhu J., Puvion F., Koken M., Honore N., Doubeikovsky A., Duprez E., Pandolfi P.P., Puvion E., Freemont P., and de The H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 193 (2001) 1361-1371
16. Zhong S., Muller S., Ronchetti S., Freemont P.S., Dejean A., and Pandolfi P.P. Role of SUMO-1-modified PML in nuclear body formation. Blood 95 (2000) 2748-2752
17. Shen T.H., Lin H.K., Scaglioni P.P., Yung T.M., and Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol. Cell 24 (2006) 331-339
18. McConnell M.J., and Licht J.D. The PLZF gene of t (11;17)-associated APL. Curr. Top. Microbiol. Immunol. 313 (2007) 31-48
19. David G., Alland L., Hong S.H., Wong C.W., DePinho R.A., and Dejean A. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16 (1998) 2549-2556
20. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Lazar M.A., Minucci S., and Pelicci P.G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391 (1998) 815-818
21. Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman S., and Zelent A. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91 (1998) 2634-2642
22. Hong S.H., David G., Wong C.W., Dejean A., and Privalsky M.L. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 94 (1997) 9028-9033
23. Lin R.J., Nagy L., Inoue S., Shao W., Miller Jr. W.H., and Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
24. Kang S.I., Chang W.J., Cho S.G., and Kim I.Y. Modification of promyelocytic leukemia zinc finger protein (PLZF) by SUMO-1 conjugation regulates its transcriptional repressor activity. J. Biol. Chem. 278 (2003) 51479-51483
25. Ruthardt M., Orleth A., Tomassoni L., Puccetti E., Riganelli D., Alcalay M., Mannucci R., Nicoletti I., Grignani F., Fagioli M., and Pelicci P.G. The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies. Oncogene 16 (1998) 1945-1953
26. Li Z., Day C.P., Yang J.Y., Tsai W.B., Lozano G., Shih H.M., and Hung M.C. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53. Cancer Res. 64 (2004) 9080-9085
27. Johansen L.M., Iwama A., Lodie T.A., Sasaki K., Felsher D.W., Golub T.R., and Tenen D.G. c-Myc is a critical target for c/EBPalpha in granulopoiesis. Mol Cell Biol. 21 (2001) 3789-3806
28. Sapetschnig A., Rischitor G., Braun H., Doll A., Schergaut M., Melchior F., and Suske G. Transcription factor Sp3 is silenced through SUMO modification by PIAS1. EMBO J. 21 (2002) 5206-5215
29. Chang L.J., Urlacher V., Iwakuma T., Cui Y., and Zucali J. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Gene. Ther. 6 (1999) 715-728
30. Dhordain P., Albagli O., Honore N., Guidez F., Lantoine D., Schmid M., The H.D., Zelent A., and Koken M.H. Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. Oncogene 19 (2000) 6240-6250
31. Dong S., Zhu J., Reid A., Strutt P., Guidez F., Zhong H.J., Wang Z.Y., Licht J., Waxman S., Chomienne C., Chen Z., Zelent A., and Chen S.J. Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-alpha fusion protein. Proc. Natl. Acad. Sci. USA 93 (1996) 3624-3629
32. McConnell M.J., Chevallier N., Berkofsky-Fessler W., Giltnane J.M., Malani R.B., Staudt L.M., and Licht J.D. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol. Cell Biol. 23 (2003) 9375-9388
33. Yeyati P.L., Shaknovich R., Boterashvili S., Li J., Ball H.J., Waxman S., Nason-Burchenal K., Dmitrovsky E., Zelent A., and Licht J.D. Leukemia translocation protein PLZF inhibits cell growth and expression of cyclin A. Oncogene 18 (1999) 925-934